Relapse Management Group Psychoeducation Program

Effects of Relapse Management Group Psychoeducation Program Applied to Schizophrenia Patients on Relapse Management and Functional Recovery

This study was planned to be conducted between February and March 2026, with a total of 60 patients diagnosed with schizophrenia who met the inclusion criteria and were followed at the community mental health center in the Psychiatry Building of Ankara Etlik City Hospital. 30 patients were in the experimental group and 30 were in the control group.

Study Overview

• Status: Not yet recruiting
• Conditions: Relapse Management
• Intervention / Treatment: Other: Relapse Management Group Psychoeducation Program

Detailed Description

Schizophrenia patients in the experimental and control group will complete the Data Collection Form before (pretest) and immediately after (posttest) the relapse management group psychoeducation program. The researchers will implement the relapse management group psychoeducation program with schizophrenia patients being followed at the community mental health center between February and March 2026. The program will include a total of four 60 minute group psychoeducation sessions. The program will cover the symptoms of schizophrenia, the definition of functioning in schizophrenia, the relationship between relapse and functioning in schizophrenia, how to manage relapse in schizophrenia, and potential interventions. The pretest will be administered before the program, and the posttest will be administered four weeks after the sessions. Schizophrenia patients in the control group will not receive the relapse management group psychoeducation program and will continue their daily care at the center. Schizophrenia patients in the control group will complete a Data Collection Form at the same time (pretest, posttest) as the experimental group.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Bahar Akkaya; Phone Number: 0312 797 0000; Email: akkayabahar2130@icloud.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

• Age 18 and over
• Able to speak and understand Turkish
• Written consent obtained
• Being a patient diagnosed with schizophrenia who is being monitored at the relevant institution during the study period
• Being in remission Exclusion Criteria
• Those who have previously received or are currently receiving psychoeducation on relapse management
• Those who do not attend community mental health center follow-ups regularly
• Those with mental retardation that may prevent participation in psychoeducation
• Those in the relapse phase of the disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Schizophrenia patients in the experimental group will complete the Data Collection Form before (pretest) and immediately after (posttest) the relapse management group psychoeducation program. The researchers will implement the relapse management group psychoeducation program with schizophrenia patients being followed at the community mental health center between February and March 2026 The program will include a total of four 60 minute group psychoeducation sessions. The program will cover the symptoms of schizophrenia, the definition of functioning in schizophrenia, the relationship between relapse and functioning in schizophrenia, how to manage relapse in schizophrenia, and potential interventions. The pre-test will be administered before the program, the post-test will be administered after the sessions, and the follow up-test will be administered four weeks after the sessions.	Other: Relapse Management Group Psychoeducation Program; Schizophrenia patients in the experimental group will complete the Data Collection Form before (pre-test) and immediately after (post-test) the relapse management group psychoeducation program. The researchers will implement the relapse management group psychoeducation program with schizophrenia patients being followed at the community mental health center between February and March 2026. The program will include a total of four 60 minute group psychoeducation sessions. The program will cover the symptoms of schizophrenia, the definition of functioning in schizophrenia, relapse in schizophrenia, the relationship between relapse and functioning, how to manage relapse in schizophrenia, and potential interventions. The pre-test will be administered before the program, the post-test will be administered after the sessions, and the follow up-test will be administered four weeks after the sessions.
No Intervention: Control group; There will be no training or intervention. Schizophrenia patients in the control group will not receive the relapse management group psychoeducation program and will continue their daily care at the center. Schizophrenia patients in the control group will complete a Data Collection Form at the same time (pretest, posttest, follow up-test) as the experimental group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Early Warning Signs of Relapse Questionnaire	This scale was developed by Abu Sabra in 2023 to assess the ability of patients and their primary caregivers to self-manage symptoms of relapse. The scale is scored by asking participants (patients and their primary caregivers). The survey consists of a total of 20 questions: 10 for patients and 10 for their relatives. The patient version (10-question section) of the scale for which the Turkish validity and reliability study will be used. The 5-point Likert-type scale is scored as follows: "I can't do it at all" ("1"), "I can do it very little" ("2"), "I can do it a little" ("3"), "I can do it moderately" ("4"), and "I can do it extremely" ("5"). The highest score for each group is 50, and the lowest is 10. The survey has no cut-off point. Higher scores represent higher levels of self-management ability. The Cronbach's Alpha coefficient of the total items of the relapse early warning signs questionnaire is 0.96 (the Cronbach's Alpha coefficient of the patient items is 0.95 and the Cro	Change from before implementation, after the practice is completed, 4 weeks after the practice is finished.
Functional Recovery Scale for Patients with Schizophrenia	Functional Recovery Scale for Patients with Schizophrenia was first developed by Llorca et al (2009). The validity and reliability of the scale in Turkey was conducted by Emiroğlu in 2009. The scale is a 5-point Likert-type scale consisting of 19 items. Each item has five levels of evaluation. Level 1 (absent) indicates the lowest level of improvement, while level 5 (excellently present) corresponds to the ideal level of functioning. Level 2 (partially present), Level 3 (sufficiently present), and Level 4 (almost completely present) are included. High scores indicate high functioning, while low scores indicate low functioning. When between two levels, the lower level is selected. The maximum score is 95, and the minimum score is 19. The scale consists of four subscales: social functioning, health and treatment, daily living skills, and occupational functioning. The social functioning subscale requires a minimum of 7 points and a maximum of 35 points; the health and treatment subscale	Change from before implementation, after the practice is completed, 4 weeks after the practice is finished.

Collaborators and Investigators

• Sponsor: Ankara Etlik City Hospital
• Collaborators: Çankırı Karatekin University

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): February 28, 2026
• Study Completion (Estimated): March 31, 2026

Study Registration Dates

• First Submitted: December 26, 2025
• First Submitted That Met QC Criteria: December 26, 2025
• First Posted (Actual): January 8, 2026

Study Record Updates

• Last Update Posted (Actual): January 8, 2026
• Last Update Submitted That Met QC Criteria: December 26, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Schizophrenia; functional recovery; randomized controlled study; psychiatric nursing; relapse management
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Schizophrenia
• Other Study ID Numbers: Etlik City Hospital

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No